Regeneron posted its Eylea updates as the company reported ... cholesterol med Praluent, suffered a 19% sales decline to $57 million in the U.S. The company also shares sales on the immunology ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% from ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

Starting in 2025, the Eylea franchise as a whole began to decline due to ... We assign Regeneron a Medium Morningstar Uncertainty Rating, as its future sales are well diversified with several ...

To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. The initial uptake of Eylea HD has been strong as Eylea patients transition to the higher dose. Sales of Eylea ...

Sales of oncology drug, Libtayo, also missed estimates. Shares are trading down in response to lower-than-expected results. Regeneron’s shares have lost 14.1% year to date compared with the industry’s ...